Subscribe to RSS
DOI: 10.1055/s-2003-40543
Onkolytische Viren als innovativer Ansatz in der Therapie gastrointestinaler Tumoren
Oncolytic viruses for genetic therapy of gastrointestinal tumorsPublication History
Manuskript-Eingang: 13. August 2002
Annahme nach Revision: 17. Oktober 2002
Publication Date:
14 July 2003 (online)

Zusammenfassung
Für die gastroenterologische Onkologie werden zusätzliche Therapiestrategien benötigt, die auf neuartigen Mechanismen basieren und keine Kreuzresistenz hinsichtlich gegenwärtiger Standardtherapien zeigen. Einen dieser Ansätze stellt die Virotherapie dar, bei der replikationskompetente virale Vektoren mit stark ausgeprägter onkolytischer Funktion zum Einsatz kommen und gegenwärtig innerhalb präklinischer und klinischer Studien evaluiert werden. Unter Einsatz der Methodik der molekularen Virologie ist eine Fortentwicklung der momentan verfügbaren Vektorsysteme insbesondere zur Verbesserung der onkolytischen Aktivität, der Tumorselektivität, der Durchwanderungsfähigkeit von Tumoren sowie der Sicherheitsaspekte erforderlich.
Abstract
Gastroenterological oncology requires new strategies with new mechanisms of action and without cross-resistance to currently available treatment regimes. Virotherapy which is based on the employment of replication-competent viral vectors exhibiting strong oncolytic properties is such an approach currently under preclinical/clinical investigation. Techniques of molecular virology are required for further improvement of current vectors, particularly with respect to oncolytic activity, tumour selectivity, tumour spread capacity, and safety.
Schlüsselwörter
Virotherapie - Onkolyse - Tumorgentherapie - vermehrungsfähige virale Vektoren
Key words
Virotherapy - oncolysis - cancer gene therapy - replication-competent viral vectors
Literatur
- 1
Lal S, Lauer U M, Wessels J T. et al .
Suicide Genes: Past, Present, and Future Perspectives.
Immunol Today.
2000;
21
48-54
MissingFormLabel
- 2
Yoon S K, Armentano D, Wands J R. et al .
Adenovirus-mediated gene transfer to orthotopic hepatocellular carcinomas in athymic
nude mice.
Cancer Gene Ther.
2001;
8
573-579
MissingFormLabel
- 3
Bilbao R, Bustos M, Alzuguren P. et al .
A blood-tumor barrier limits gene transfer to experimental liver cancer: the effect
of vasoactive compounds.
Gene Ther.
2000;
7
1824-1832
MissingFormLabel
- 4
Erbs P, Regulier E, Kintz J. et al .
In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast
cytosine deaminase/uracil phosphoribosyltransferase fusion gene.
Cancer Res.
2000;
60
3813-3822
MissingFormLabel
- 5
van Dillin I J, Mulder N H, Vaalburg W. et al .
Influence of the bystander effect on HSV-tk/GCV gene therapy. A review.
Curr Gene Ther.
2002;
2
307-322
MissingFormLabel
- 6
Elliot G, O’Hare P.
Intercellular trafficking and protein delivery by a Herpesvirus structural protein.
Cell.
1997;
88
223-233
MissingFormLabel
- 7
Wybranietz W A, Groß C D, Phelan A. et al .
Enhanced suicide gene effect by adenoviral transduction of a VP22-Cytosine deaminase
(CD) fusion gene.
Gene Ther.
2001;
8
1654-1664
MissingFormLabel
- 8
Oess S, Hildt E.
Identification of a novel cell permeable peptide derived from the Hepatitis B virus
surface antigen.
Gene Ther.
2000;
7
750-758
MissingFormLabel
- 9
Kirn D.
Clinical research results with dl1520 (ONYX-015), a replication-selective adenovirus
for the treatment of cancer: What have we learned?.
Gene Ther.
2001;
8
89-98
MissingFormLabel
- 10
Ring C JA.
Cytolytic viruses as potential anti-cancer agents.
J Gen Virol.
2002;
83
491-502
MissingFormLabel
- 11
Baum C.
Replikative Viren in der Krebstherapie.
Forum DKG.
2002;
Sonderheft 1/02
58
MissingFormLabel
- 12
Sinkovics J, Horvath J.
New developments in the virus therapy of cancer: a historical review.
Intervirol.
1993;
36
193-214
MissingFormLabel
- 13
Southam C M.
Present status of oncolytic virus studies.
NY Acad Sci.
1960;
22
656-673
MissingFormLabel
- 14
Bluming A Z, Ziegler J L.
Regressin of Burkitt's lymphoma in association with measles infection.
Lancet.
1971;
ii
105-106
MissingFormLabel
- 15
Taqi A M, Abdurrahman M B, Yakubu A M. et al .
Regression of Hodgkin's disease after measles.
Lancet.
1981;
i
1112
MissingFormLabel
- 16
Kirn D H.
Replicating oncolytic viruses: an overview.
Expert Opin Investig Drugs.
1996;
5
753-762
MissingFormLabel
- 17
Tollefson A, Scaria A, Hermiston T W. et al .
The adenovirus death protein (E3 - 11.6K) is required at late stages of infection
for efficient lysis and release of adenovirus from infected cells.
J Virol.
1996;
70
2296-2306
MissingFormLabel
- 18
Everett H, McFadden G.
Apoptosis: an innate immune response to virus infection.
Trends in Microbiol.
1999;
7
160-165
MissingFormLabel
- 19
Basu S, Binder R J, Suto R. et al .
Necrotic but not apoptotic cell death releases heat shock proteins, which deliver
a partial maturation signal to dendritic cells and activate the NF-kappa B pathway.
Int Immunol.
2000;
12
1539-1546
MissingFormLabel
- 20
Berwin B, Reed R C, Nicchitta C V.
Virally induced lytic cell death elicits the release of immunogenic grp94/gp96.
J Biol Chem.
2001;
276
21083-21088
MissingFormLabel
- 21
Lorence R M, Rood P A, Kelley K W.
Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-α
and augmentation of its cytotoxicity.
J Natl Cancer Institute.
1988;
80
1305-1312
MissingFormLabel
- 22
Stojdl D F, Lichty B, Knowles S. et al .
Exploiting tumor-specific defects in the interferon pathway with a previously unknown
oncolytic virus.
Nature Medicine.
2000;
6
821-825
MissingFormLabel
- 23
Coffey M, Strong J, Forsyth P. et al .
Reovirus therapy of tumors with activated ras pathway.
Science.
1998;
282
1332-1334
MissingFormLabel
- 24
Rommelaere J, Cornelis J J.
Antineoplastic activity of parvoviruses.
J Virol Methods.
1991;
33
233-251
MissingFormLabel
- 25
Strong J E, Coffey M C, Tang D. et al .
The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by
reovirus.
EMBO J.
1998;
12
3351-3362
MissingFormLabel
- 26
Pecora A L, Rizvi N R, Cohen G I. et al .
Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients
with advanced solid cancers.
J Clin Oncology.
2002;
20
2251-2266
MissingFormLabel
- 27
Hallenbeck P L, Chang Y N, Hay C. et al .
A novel tumor-specific replication-restricted adenoviral vector for gene therapy of
hepatocellular carcinoma.
Human Gene Ther.
1999;
10
1721-1733
MissingFormLabel
- 28
Yamada Y, Takahashi M, Sato Y. et al .
Augmented apoptosis-inducing gene therapy for HCC by p53 under control of AFP promoter
in combination with a selectively replication-competent oncolytic adenovirus and chemotherapeutic
agent.
Mol Ther.
2002;
5
S268
MissingFormLabel
- 29
Ohguchi S, Nakatsukasa H, Higashi T. et al .
Expression of alpha-fetoprotein and albumin genes in human hepatocellular carcinomas:
limitations in the application of the genes for targeting human hepatocellular carcinoma
in gene therapy.
Hepatology.
1998;
27
599-607
MissingFormLabel
- 30
Brunori M, Malerba M, Kashiwazaki H. et al .
Replicating adenoviruses that target tumors with constitutive activation of the wnt
signaling pathway.
J Virology.
2001;
75
2857-2865
MissingFormLabel
- 31
Powell S, Wang Z, Lemos B. et al .
A conditionally replicative adenovirus driven by the human telomerase promoter provides
broad-spectrum anti-tumor activity.
Mol Ther.
2002;
5
S19
MissingFormLabel
- 32
Bischoff J R, Kirn D H, Williams A. et al .
An adenovirus mutant that replicates selectively in p53-deficient human tumor cells.
Science.
1996;
274
373-376
MissingFormLabel
- 33
Biederer C, Ries S, Brandts C H. et al .
Replication-selective viruses for cancer therapy.
J Mol Med.
2002;
80
163-175
MissingFormLabel
- 34
Ganly I, Kirn D, Eckhardt S.
A phase I study of ONYX-015, an E1B attenuated adenovirus, administered intratumorally
to patients with recurrent head and neck cancer.
Clin Cancer Res.
2000;
6
798-806
MissingFormLabel
- 35
Vasey P, Shukman L, Gore M. et al .
Phase I trial of intraperitoneal ONYX-015 adenovirus in patients with recurrent ovarian
carcinoma.
Proceedings American Society of Clinical Oncology.
2000;
19
1512
MissingFormLabel
- 36
Reid T. et al .
Hepatric artery infusion of ONYX-015, a replication-selective adenovirus, in combination
with 5-FU/leucovorin for gastrointestoinal carcinoma metastatic to the liver: A Phase
I/II clinical trial.
Proceedings American Society of Clinical Oncology.
2000;
19
953
MissingFormLabel
- 37
Nemunaitis J, Ganly I, Khuri F. et al .
Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD
gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II
trial.
Cancer Res.
2000;
60
6359-6366
MissingFormLabel
- 38
Khuri F, Nemunaitis J, Ganly I. et al .
A controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus,
in combination with cisplatin and 5-fluorouracil in patients with recurrent head and
neck cancer.
Nature Medicine.
2000;
6
879-885
MissingFormLabel
- 39
Nemunaitis J, Cunningham C, Buchanan A. et al .
Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients:
safety, feasibility and biological activity.
Gene Ther.
2001;
8
746-759
MissingFormLabel
- 40
Hecht R. et al .
A phase I/II trial of intratumoral endoscopic injection of ONYX-015 with intravenous
gemcitabine in unresectable pancreatic carcinoma.
Proceedings American Society of Clinical Oncology.
2000;
19
1039
MissingFormLabel
- 41
Mulvihill S, Warren R, Venook A. et al .
Safety and feasibility of injection with an E1B-55 kD gene-deleted, replication-selective
adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial.
Gene Ther.
2001;
8
308-315
MissingFormLabel
- 42
Yoon S S, Nakamura H, Coroll N M. et al .
An oncolytic herpes simplex virus type I selectivley destroys diffuse liver metastases
from colon carcinoma.
FASEB J.
2000;
14
301-311
MissingFormLabel
- 43
Pawlik T M, Nakamura H, Yoon S S. et al .
Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a
replication-competent, genetically engineered herpesvirus.
Cancer Res.
2000;
60
2790-2795
MissingFormLabel
- 44
DeRubertis B G, Stiles B M, Bhargava A. et al .
Cytokine secreting oncolytic Herpes Virus effectively treats micrometastatic liver
disease in a murine model.
Mol Ther.
2002;
5
S101-S102
MissingFormLabel
- 45
Horsburgh B C, Fong Y, Malhotra S. et al .
Multiple administration of NV1020, an oncolytic HSV-1, results in increased anti-tumor
efficacy in rodents with colorectal metastases to liver.
Mol Ther.
2002;
5
S148
MissingFormLabel
- 46
Markert J. et al .
Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malingnant
glioma. Results of a phase I trial.
Gene Ther.
2000;
7
867-874
MissingFormLabel
- 47
Mastrangelo M, Eisenlohr L, Gomella L. et al .
Poxvirus vevtors: Orphaned and underaprreciated.
J Clin Invest.
2000;
105
1031-1034
MissingFormLabel
- 48
Conry R M. et al .
Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in
metastatic: Comparison of intradermal versus subcutaneous administration.
Clin Cancer Res.
1999;
5
2330-2337
MissingFormLabel
- 49
Hirasawa K, Yoon C, Nishikawa S G. et al .
Reovirus therapy of metastatic cancer models in immune-competent mice.
Proc. Am Assoc Cancer Res.
2001;
42
2437a
MissingFormLabel
- 50
Aktelle Informationen des National Cancer Institutes zu dem Klinischen Einsatz von
NDV finden sich unter folgender Homepage- Adresse: http://www.cancer.gov/cancer_information/doc.aspx?viewid
= 284ad06f-682d-43df-bccf-4943a09c1e98.
MissingFormLabel
- 51
Roberts M S, Buasen P T, Incao B A. et al .
PV 701, a naturally attenuated strain of Newcastle disease virus, has a broad spectrum
of oncolytic activity against human tumor xenografts.
Proc Am Assoc Cancer Res.
2001;
42
2441a
MissingFormLabel
- 52
Phuangsab A, Lorence R M, Reichard K W. et al .
Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local
or systemic administration.
Cancer Letters.
2001;
172
27-36
MissingFormLabel
- 53
Bateman A, Bullough F, Murphy S. et al .
Fusogenic membrane glycoproteins as a novel class of genes for local and immune-mediated
control of tumor growth.
Cancer Res.
2000;
60
1492-1497
MissingFormLabel
- 54
Enders J, Peebles T.
Propagation in tissue culture of cytopathic agents from patients with measles.
Proc Soc Exp Biol Med.
1954;
86
277-286
MissingFormLabel
- 55
Grote D, Russell S J, Corni T I. et al .
Live attenuated measle virus induces regression of human lymphoma xenografts in immunodeficient
mice.
Blodd.
2001;
97
3746-3754
MissingFormLabel
- 56
Peng K W, Facteau S, Wegman T. et al .
Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides.
Nature Medicine.
2002;
8
527-531
MissingFormLabel
- 57
Peng K W, TenEyck C T, Galanis E. et al .
Intraperitoneal Therapy of Ovarian Cancer Using an Engineered Measles Virus.
Mol Ther.
2002;
5
S444
MissingFormLabel
- 58
Balachandran S, Porosnicu M, Barber G N.
Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting
aberrrant p53, Ras, or Myc function and involves induction of apoptosis.
J Virol.
2001;
75
3474-3479
MissingFormLabel
- 59
Fernandez M, Porosnicu M, Markovic D. et al .
Genetically engineered vesicular stomatitis virus in gene therapy: application for
treatment of malignant disease.
J Virol.
2002;
76
895-904
MissingFormLabel
- 60 Weiss R A. Introducing viruses and cancer. Arrand JR, Harper DR Viruses and Human Cancer Oxford; Bios Scientific Publishers 1-15
MissingFormLabel
- 61
Heise C, Williams A, Olesch J. et al .
Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection:
Intratumoral spread and distribution effects.
Cancer Gene Ther.
1999;
6
499-504
MissingFormLabel
- 62
Douglas J, Kim M, Sumerel L. et al .
Efficient oncolysis by a replicating adenovirus in vivo is critically dependent on
tumor expression of primary Ad receptors.
Cancer Res.
2001;
61
499-504
MissingFormLabel
- 63
Yu D. et al .
Antitumor synergy of CN787, a prostate cancer-specific adenovirus, and paclitaxel
and docetaxel.
Cancer Res.
2001;
61
517-525
MissingFormLabel
- 64
Heise C, Lemmon M, Kirn D.
Replication-selective adenovirus plus cisplatin chemotherapy efficacy is dependent
on sequencing but independent of p53 status.
Clin Cancer Res.
2000;
6
4908-4914
MissingFormLabel
- 65
Sugarbaker P H, Schellinx M E, Chang D. et al .
Peritonela carcinomatosis from adenocarcinoma of the colon.
World J Surgery.
1996;
20
585-592
MissingFormLabel
- 66
Rogulski K R, Freytag S O, Zhang K. et al .
In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented
by radiotherapy.
Cancer Res.
2000;
60
1193-1196
MissingFormLabel
- 67
Barajas M, Mazzolini G, Genove G. et al .
Gene therapy of orthotopic hepatocellular carcinomas in rats using adenovirus coding
for interleukin 12.
Hepatology.
2001;
33
52-61
MissingFormLabel
- 68
Habib N A, Mitry R R, Sarraf C E. et al .
Assessment of growth inhibition and morphological changes in in vitro and in vivo
hepatocellular carcinoma models post treatment with dl1520 adenovirus.
Cancer Gene Ther.
2002;
9
414-420
MissingFormLabel
- 69
Habib N A, Sarraf C E, Mitry R R. et al .
E1B deleted adenovirus (dl1520) gene therapy for patients with primary and secondary
liver tumors.
Hum Gene Ther.
2001;
12
219-226
MissingFormLabel
- 70
Reid T, Galanis E, Abbruzzese J. et al .
Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients
with colorectal carcinoma metastatic to the liver: a phase 1 trial.
Gene Ther.
2001;
8 (21)
1618-1626
MissingFormLabel
PD Dr. med. Ulrich M. Lauer
Abteilung Innere Medizin I, Medizinische Universitätsklinik, Universitätsklinikum
Tübingen
Otfried-Müller-Straße 10
72076 Tübingen
Email: ulrich.lauer@uni-tuebingen.de